Studies treatments for prostate cancer that has spread and responds to hormones
Looks at chemotherapy, hormone-blocking drugs, or radiotherapy in men with spread prostate cancer.
Plain-language title generated from the registry record
Registry title: Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Key facts
- Where
- Orbassano, Padova, and Trento, ItalySee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for men with prostate cancer that has spread and still responds to hormone therapy. They were treated with docetaxel, an ARPI, or radiotherapy on the primary tumor, together with ADT.
- Sex
- Men only.
- Disease stage
- Prostate adenocarcinoma confirmed by tissue examination. The cancer has spread (metastatic) and is hormone-sensitive.
- Earlier treatment
- No earlier treatment for the spread disease, except hormone therapy started no more than 4-6 months before docetaxel. Treatment with docetaxel, ARPI (alone or combined) or radiotherapy on the primary tumor plus ADT started between January 2015 and December 2027.
Main reasons for not taking part
- Cancer type other than adenocarcinoma
- Multiple lines of ADT for hormone-sensitive disease
- Docetaxel or ARTA given for castration-resistant metastatic disease
- No inpatient or outpatient medical records available
Read by machine on 12 November 2026.
Where in Italy
- Azienda Ospedaliera San LuigiOrbassano, ItalyContact: Consuelo Buttigliero, MD, PhDTaking people
- Istituto Oncologico VenetoPadova, ItalyContact: Umberto Basso, MDTaking people
- Santa Chiara HospitalTrento, ItalyContact: Orazio Caffo, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Santa Chiara Hospital
- Trial code
- NCT06473259
- Record updated
- 25 June 2024
- Original description
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practiceRead full original descriptionShow less
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Inclusion: histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease; treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027; availability of inpatient and/or outpatient medical records for clinical data collection.
Exclusion: patients who have received multiple lines of ADT for mCSPC; patients who have received docetaxel or ARTA for metastatic castration-resistant disease; histological diagnosis other than adenocarcinoma.